-
ATTEMPT trial shows kidney, glycemic benefits for SGLT2 inhibitor in adolescents with type 1 diabetes
Jennifer L. Sherr, MD, PhD, and other investigators shared the latest data from the first randomized controlled trial of a sodium-glucose cotransporter protein-2 (SGLT2) inhibitor in adolescents with type 1 diabetes at the 84th Scientific Sessions.
-
TIGHT investigators share lessons learned from evaluating inpatient CGM
Despite a lack of improvement in glycemic management in TIGHT, Guillermo Umpierrez, MD, CDCES, MACP, FACE, said he was optimistic about the future of determining hypoglycemia and hyperglycemia for hospitalized patients with diabetes.
-
FLOW trial demonstrates kidney, cardiovascular benefits of semaglutide in high-risk patients with type 2 diabetes
Investigators presented findings from the first-ever dedicated kidney outcomes trial with a glucagon-like peptide-1 (GLP-1) receptor agonist. The trial was stopped early for clear positive efficacy, including slowed progression of kidney disease.
-
STEP trials show heart failure benefit with or without diabetes, could transform HFpEF treatment
Two trials of semaglutide show similar improvement in heart failure symptoms and weight loss in patients with BMI >30 who have heart failure with preserved ejection fraction with or without diabetes, reported Mikhail N. Kosiborod, MD, and other investigators.
-
New results from SELECT show reduction in progression to diabetes
Semaglutide is best known as a weight loss drug, yet SELECT was not a weight loss study. It was a secondary cardioprevention trial, explained Donna H. Ryan, MD, one of the experts presenting results from SELECT.
-
SURMOUNT-OSA findings demonstrate benefit of tirzepatide in treatment of obesity-related OSA
The drug has been shown to improve sleep apnea severity and related cardiometabolic issues in people with moderate-to-severe obstructive sleep apnea, reported investigators including Atul Malhotra, MD, and Louis J. Aronne, MD, FACP, DABOM.